Opinion|Videos|October 18, 2024
Payer and Patient Education Considerations for SCLC
Key Takeaways
- Establishing clear communication with payers and providing comprehensive clinical evidence can facilitate medication access for SCLC patients.
- Utilizing educational materials from reputable cancer organizations and support groups enhances patient understanding of SCLC.
Panelists discuss how to effectively collaborate with payers to ensure access to necessary medications for patients with small cell lung cancer (SCLC), while also exploring best practices for patient education and identifying valuable resources to share with those diagnosed with SCLC.
Advertisement
Episodes in this series
What are best practices for working with payers to ensure that patients with small cell lung cancer (SCLC) get access to the necessary medications?
How do you educate patients about SCLC, and which resources do you find useful in sharing with patients?
Advertisement
Related to this article
The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”
The FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.
Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
This system-level initiative significantly increased guideline-concordant venous thromboembolism prophylaxis rates in hospitalized patients through coordinated education, clinical decision tools, audit-feedback, and pharmacist integration.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.
He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.
Advertisement
Advertisement
Trending on AJMC
1
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
FDA Approves Talazoparib Plus Enzalutamide for HRR-Mutated mHSPC
5